Tamoxifen and fenretinide in women with metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 57, Issue 3, 1999, Pages 277-283

  Zujewski, J ^a,c   Pai, L ^a   Wakefield, L ^a   Giusti, R ^a   Dorr, F A ^a   Flanders, C ^a   Caruso, R ^b   Kaiser, M ^b   Goodman, L ^b   Merino, M ^a   Gossard, M ^a   Noone, M A ^a   Denicoff, A ^a   Venzon, D ^a   Cowan, K H ^a   O'Shaughnessy, J A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL EYE INSTITUTE   (United States)

^c Bldg 10 Rm 12N/226 ^*  (United States)

Author keywords

Breast cancer; Dark adaptation; Fenretinide; Lipids; Tamoxifen; Transforming growth factor

Indexed keywords

CHOLESTEROL; ESTROGEN RECEPTOR; FENRETINIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DARK ADAPTATION; DEPRESSION; DIARRHEA; FATIGUE; FEMALE; HOT FLUSH; HUMAN; LIP DISEASE; LIPID BLOOD LEVEL; METASTASIS; NAUSEA; NIGHT BLINDNESS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; TRIACYLGLYCEROL BLOOD LEVEL; VISUAL DISORDER;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; FENRETINIDE; HUMANS; LIPIDS; MIDDLE AGED; PILOT PROJECTS; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 0032761099     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006216409688     Document Type: Article

References (31)

1. 1. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351: 1451-1467, 1998
2. 2. De Luca LM: Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. FASEB J 5: 2924-2933, 1991
3. 3. Smith MA, Parkinson DR, Cheson BD, Friedman MA: Retinoids in cancer therapy. J Clin Oncol 10: 839-864, 1992
4. 4. Lippman SM, Kessler JF, Meyskens FL: Retinoids as prevention and therapeutic anticancer agents. Cancer Treat Rep 71: 391-405, (Part I); 493-515 (Part II), 1987
5. 4. Lippman SM, Kessler JF, Meyskens FL: Retinoids as prevention and therapeutic anticancer agents. Cancer Treat Rep 71:391-405, (Part I); 493-515 (Part II), 1987
6. 5. Dowlatshari K, Mehta RG, Thomas CF, Dinger NM, Moon RC: Therapeutic effect of N-(4-hydroxyphenyl)retinamide on N-methyl-N-nitrosourea-induced rat mammary cancer. Cancer Let 47: 187-192, 1989
7. 6. Moon RC, Thompson HJ, Becci PJ, Grubbs CJ, Gender RJ, Newton DL, Smith JM, Phillips SL, Henderson WR, Mullen LT, Brown CC, Sporn MB: N-(4-hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res 39: 1339-1346, 1979
8. 7. Ratko TA, Detrisac CJ, Dinger NM, Thomas CF, Kelloff GJ, Moon RC: Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res 49: 4472-4476, 1989
9. 8. Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF, Sigman CC: Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res 12: 1147-1154, 1992
10. 9. Modiano MR, Dalton WS, Lippman SM, Joffe L, Booth AR, Meyskens FL Jr: Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma. Invest New Drugs 8: 317-319, 1990.
11. 10. Cobleigh MA, Dowlatshahi K, Deutsch TA, Mehta RG, Moon RC, Minn F, Benson AB III, Rademaker AW, Ashenhurst JB, Wade JL, Walker J: Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol 11: 474-477, 1993
12. 11. Torrisi R, Parodi S, Fontana J, Pensa F, et al.: Effect of Fenretinide on plasma IGF-1 and IGFBP-3 in early breast cancer patients. Int J Cancer 76: 787-790, 1998
13. 12. Torrisi R, Pensa F, Fontana V, Costa A, Decensi A: The metabolite N-40 methoxyphenylretinamide is a major determinant of fenretinide induced decline of plasma insulin-like growth factor-1. Eur J Cancer 31A: 420-421, 1995
14. 13. Decensi A, Formelli F, Torrisi R, Costa A: Breast cancer chemoprevention: Studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints. J Cell Biol 17G: 226-233, 1993
15. 14. Pollak M, Costantino J, Polychronakos C, Bauer SA, Guyda H, Redmond C, Fisher B, Margolese R: Effect of tamoxifen on serum insulin-like growth factor I levels in Stage I breast cancer patients. J Natl Cancer Inst 82: 1693-1697, 1990
16. 15. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB: Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417-428, 1987
17. 16. Arteaga CL, Tandon AK, Von Hoff D, Osborne CK: Transforming growth factor B: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res 48: 3898-3904, 1988
18. 17. Glick AB, McCune BK, Abdulkarem N, Flanders KC, Lunadue JA, Smith JM, Sporn MB: Complex regulation of TGF-β expression by retinoic acid in the vitamin A deficient rat. Development 111: 1081-1086, 1992
19. 18. Butta A, MacLennan K, Flanders KC, Sacks NPM, Smith I, McKinna A, Dowsett M, Wakefield LM, Sporn MB, Baum M, Colletta AA: Induction of transforming growth factor -β1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52: 4261-4264, 1992
20. 19. Rotmensz N, DePalo G, Formelli F, Costa A, Marubini E, Campa T, Crippa A, Danesini GM, Grottaglie M Delle, DiMauro MG, Filiberti A, Gallazzi M, Gozzon A, Magni A, Malone W, Mariani L, Palvarini, Perloff M, Pizzichetta M, Veronesi U: Long-term tolerability of fenretinide (4-HPR) in breast cancer patients. Eur J Cancer 27: 1127-1131, 1991
21. 20. Wakefield LM, Letterio JJ, Chen T, Danielpour D, Allison RSH, Pai LH, Denicoff AM, Noone MH, Cowan KH, O'Shaughnessy JA, Sporn MD: Transforming growth factor β1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 1: 129-136, 1995
22. 21. Decensi A, Torrisi R, Polizzi A, Gesi R, Brezzo V, Rolando M, Rondanina G, Orengo MA, Formelli F, Costa A: Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface. J Natl Cancer Inst 86: 105-110, 1994
23. 22. Caruso RC, Zujewski J, Iwata F, Podgon MJ, Conley BA, Ayres LM, Kaiser-Kupfer MI: Effects of fenretinide (4-HPR) on dark adaptation. Arch Ophthalmol 116: 759-763, 1998
24. 23. Thangaraju M, Kumar K, Gandhirajan R, Sachdanandam P: Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. Cancer 73: 659-663, 1994
25. 24. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappel RJ: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 86: 1534-1539, 1995
26. 25. Bruning PF, Bonfrer JM, Hart AA, Bakker MD, Linders D, Loos JV, et al.: Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 58: 497-499, 1988
27. 26. Rossner S, Wallgren A: Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 53: 339-346, 1984
28. 27. Wander HE: Changes in the serum lipoprotein under tamoxifen (Abstract). Second International Symposium on Antihormones in Breast Cancer, Berlin, October 21-24, 1984
29. 28. Kong FM, Anscher MS, Murase T, Abbott BD, Inglehart JD, Jirtle RL: Elevated plasma transforming growth factor-beta levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 222: 155-162, 1995
30. 29. Kopp A, Jonat W, Schmahl M, Knabbe C: Transforming growth factor β2 (TGF-β2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res 55: 4512-4515, 1995
31. 30. Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL: Transforming growth factor β as a predictor of liver and lunger fibrosis after autologous bone marrow transplantation for advanced breast cancer. New Engl J Med 328: 1592-1598, 1993